Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG

• Status: Completed
• Trial end date: 2020-04-25
• Target enrollment: 0
• Participant gender: All

Summary

Background: In cardiac surgery, myocardial protection is mandatory during cross clamp time followed by reperfusion. Use of cardioplegic solutions preserves myocardial energy stores, hindering electrolyte disturbances and acidosis during periods of myocardial ischemia. This study was designed to compare the efficacy and safety of Histidine-tryptophan-ketoglutarate (HTK) solution versus blood cardioplegia in coronary artery bypass graft surgery.

Methods: Three hundred and twenty patients were randomized into Histidine-tryptophan-ketoglutarate (HTK) group and blood cardioplegia group. Ventilation time, total bypass time, cross clamp time, length of ICU or hospital stay and the early postoperative outcomes were analysed.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Cardioplegic Solutions; Mannitol; Pharmaceutical Solutions; Procaine; Tryptophan

Criteria

Inclusion Criteria:

• age from 60-80 years old

• elective CABG

• no comorbidities

Exclusion Criteria:

• patients with Unstable angina

• Poor left ventricular function

• Patient with acute myocardial infarction

• previous renal failure

• Preoperative Aortic valve or Mitral valve disease requiring replacement